Hang Seng Index
WuXi Biologics
A global biologics CDMO providing development and manufacturing for antibody and other biopharmaceutical drugs. Hang Seng Index constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
2269.HK Updated Jul 11, 2026 2 AI consumers· 2 recurring
Annual return · 2026-07-10'21-30.7%'22-13.7%'23-68.6%'24-10.1%'25+100.9%YTD+2.6%
Money in ▸·
WuXi Biologicsapprox. CN¥17.0B
▸ Money out·
Financials & Segments
- Total revenue · approx. CN¥17.0B (FY2023)
- Segments · Pre-IND (early development) · Post-IND (late-stage & commercial)
Revenue from
No refined links yet.
Pays to
No refined links yet.